Evaxion Biotech Announces One-year Data From The Ongoing Phase 2 Trial With Its Lead Asset EVX-01, Personalized Cancer Vaccine
Portfolio Pulse from Benzinga Newsdesk
Evaxion Biotech reported promising one-year data from its Phase 2 trial of EVX-01, a personalized cancer vaccine. The trial showed a 69% overall response rate, with 15 out of 16 patients experiencing tumor reduction. The vaccine's targets triggered a strong immune response, indicating significant commercial potential for melanoma treatment.
September 16, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Evaxion Biotech's EVX-01 cancer vaccine shows a 69% response rate in Phase 2 trials, with significant tumor reduction in patients. The vaccine's strong immune response suggests commercial potential in melanoma treatment.
The positive trial results for EVX-01, including a high response rate and tumor reduction, suggest strong potential for future revenue growth and market impact. This is likely to positively influence Evaxion's stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100